<?xml version="1.0" encoding="UTF-8"?>
<p id="para180">Earlier in the drug's development, however, researchers had tested remdesivir against the coronaviruses that cause SARS and MERS, another respiratory disease. Studies both in cells and in mice showed that 
 <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28659436/" id="interrefs130" xmlns:xlink="http://www.w3.org/1999/xlink">the drug</ext-link>
 <ext-link ext-link-type="uri" xlink:href="https://mbio.asm.org/content/9/2/e00221-18" id="interrefs140" xmlns:xlink="http://www.w3.org/1999/xlink">could prevent the viruses replicating</ext-link> â€“ driving hopes that it could work against the new coronavirus too. These findings, plus the fact that the drug has already passed safety trials as part of its testing against Ebola, have rapidly made it the front runner in the race for covid-19 therapeutics. Four large clinical trials evaluating remdesivir are getting under way in the US and these, combined with trials in China, should give preliminary results as soon as the end of this month.
</p>
